Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2013-01-11

FDA Approved: OXYCONTIN — Supplemental Application (Purdue Pharma LP)

View source ↗

Summary

The FDA approved a supplemental application for OxyContin (oxycodone hydrochloride) from Purdue Pharma to update the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • OXYCONTIN (OXYCODONE HYDROCHLORIDE)

Snippet

SUPPL AP for OXYCONTIN (OXYCODONE HYDROCHLORIDE)